{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:35:26Z","timestamp":1790796926784,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.clineuro.2022.107169","type":"journal-article","created":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T12:14:07Z","timestamp":1644236047000},"page":"107169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Effectiveness and safety of erenumab in chronic migraine: A Croatian real-world experience"],"prefix":"10.1016","volume":"214","author":[{"given":"Darija","family":"Mahovi\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matea","family":"Bra\u010di\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukrecija","family":"Jaku\u0161","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlasta","family":"Vukovic Cvetkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Krpan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.clineuro.2022.107169_bib1","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","article-title":"Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the global burden of disease study 2016","volume":"17","author":"Stovner","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.clineuro.2022.107169_bib2","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS), The International Classification of Headache Disorders, 3rd edition, Cephalalgia. 38(1) (2018) 1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202.","DOI":"10.1177\/0333102417738202"},{"key":"10.1016\/j.clineuro.2022.107169_bib3","doi-asserted-by":"crossref","first-page":"g1416","DOI":"10.1136\/bmj.g1416","article-title":"Chronic migraine","volume":"348","author":"Schwedt","year":"2014","journal-title":"BMJ"},{"issue":"S2","key":"10.1016\/j.clineuro.2022.107169_bib4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/head.12505_2","article-title":"Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention","volume":"55","author":"Lipton","year":"2015","journal-title":"Headache"},{"issue":"1","key":"10.1016\/j.clineuro.2022.107169_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1526-4610.2011.02046.x","article-title":"Headache impact of chronic and episodic migraine: results from the american migraine prevalence and prevention study","volume":"52","author":"Buse","year":"2012","journal-title":"Headache"},{"issue":"4","key":"10.1016\/j.clineuro.2022.107169_bib6","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1212\/CON.0000000000000192","article-title":"Acute migraine treatment","volume":"21","author":"Becker","year":"2015","journal-title":"Contin. Lifelong Learn Neurol."},{"issue":"4","key":"10.1016\/j.clineuro.2022.107169_bib7","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1212\/CON.0000000000000199","article-title":"Preventive migraine treatment","volume":"21","author":"Silberstein","year":"2015","journal-title":"Contin. Lifelong Learn Neurol."},{"issue":"1","key":"10.1016\/j.clineuro.2022.107169_bib8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s10194-018-0875-x","article-title":"Medication-overuse headache: a widely recognized entity amidst ongoing debate","volume":"19","author":"Vandenbussche","year":"2018","journal-title":"J. Headache Pain."},{"issue":"9","key":"10.1016\/j.clineuro.2022.107169_bib9","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1111\/j.1526-4610.2008.01274.x","article-title":"Refractory migraine and chronic migraine: pathophysiological mechanisms","volume":"48","author":"Goadsby","year":"2008","journal-title":"Headache"},{"issue":"8","key":"10.1016\/j.clineuro.2022.107169_bib10","first-page":"795","article-title":"Calcitonin gene-related peptide antagonists for the prevention of migraine: highlights from pivotal studies and the clinical relevance of this new drug class","volume":"54","author":"Arca","year":"2020","journal-title":"Ann. Pharm."},{"issue":"1","key":"10.1016\/j.clineuro.2022.107169_bib11","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s10194-018-0955-y","article-title":"European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention","volume":"20","author":"Sacco","year":"2019","journal-title":"J. Headache Pain"},{"issue":"4","key":"10.1016\/j.clineuro.2022.107169_bib12","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s40265-019-01069-1","article-title":"Erenumab for preventive treatment of migraine: a systematic review and meta-analysis of efficacy and safety","volume":"79","author":"Lattanzi","year":"2019","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.clineuro.2022.107169_bib13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12883-020-01633-3","article-title":"Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis","volume":"20","author":"Deng","year":"2020","journal-title":"BMC Neurol."},{"issue":"6","key":"10.1016\/j.clineuro.2022.107169_bib14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Tepper","year":"2017","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.clineuro.2022.107169_bib15","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s10194-018-0923-6","article-title":"Early onset of efficacy with erenumab in patients with episodic and chronic migraine","volume":"19","author":"Schwedt","year":"2018","journal-title":"J. Headache Pain"},{"issue":"22","key":"10.1016\/j.clineuro.2022.107169_bib16","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","article-title":"A controlled trial of Erenumab for episodic migraine","volume":"377","author":"Goadsby","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"10161","key":"10.1016\/j.clineuro.2022.107169_bib17","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","article-title":"Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study","volume":"392","author":"Reuter","year":"2018","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.clineuro.2022.107169_bib18","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1177\/0333102419835459","article-title":"Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study","volume":"39","author":"Goadsby","year":"2019","journal-title":"Cephalalgia"},{"issue":"5","key":"10.1016\/j.clineuro.2022.107169_bib19","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1212\/WNL.0000000000010019","article-title":"One-year sustained efficacy of erenumab in episodic migraine: results of the STRIVE study","volume":"95","author":"Goadsby","year":"2020","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.clineuro.2022.107169_bib20","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1177\/0333102418788347","article-title":"Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study","volume":"38","author":"Ashina","year":"2018","journal-title":"Cephalalgia"},{"issue":"1","key":"10.1016\/j.clineuro.2022.107169_bib21","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s10194-020-01102-9","article-title":"Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy","volume":"21","author":"Ornello","year":"2020","journal-title":"J. Headache Pain"},{"issue":"1","key":"10.1016\/j.clineuro.2022.107169_bib22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s10194-020-01143-0","article-title":"Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience","volume":"21","author":"Russo","year":"2020","journal-title":"J. Headache Pain"},{"issue":"1","key":"10.1016\/j.clineuro.2022.107169_bib23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s10194-020-01127-0","article-title":"A prospective real-world analysis of erenumab in refractory chronic migraine","volume":"21","author":"Lambru","year":"2020","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.clineuro.2022.107169_bib24","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.3389\/fneur.2021.805334","article-title":"Erenumab for migraine prevention in a 1-year compassionate use program: efficacy, tolerability, and differences between clinical phenotypes","volume":"12","author":"Schoenen","year":"2021","journal-title":"Front Neurol."},{"issue":"1","key":"10.1016\/j.clineuro.2022.107169_bib25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s10194-020-01214-2","article-title":"Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment \u2013 real world outcomes","volume":"22","author":"Talbot","year":"2021","journal-title":"J. Headache Pain"},{"issue":"2","key":"10.1016\/j.clineuro.2022.107169_bib26","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/head.14032","article-title":"Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study","volume":"61","author":"Barbanti","year":"2021","journal-title":"Headache"},{"issue":"1","key":"10.1016\/j.clineuro.2022.107169_bib27","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s10194-020-01151-0","article-title":"Erenumab in highly therapy-refractory migraine patients: First German real-world evidence","volume":"21","author":"Scheffler","year":"2020","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.clineuro.2022.107169_bib28","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3389\/fneur.2020.00417","article-title":"Erenumab in chronic migraine patients who previously failed five first-line oral Prophylactics and OnabotulinumtoxinA: a dual-center retrospective observational study","volume":"11","author":"Raffaelli","year":"2020","journal-title":"Front Neurol."},{"issue":"9","key":"10.1016\/j.clineuro.2022.107169_bib29","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1111\/head.13951","article-title":"Real-world patient experience with erenumab for the preventive treatment of migraine","volume":"60","author":"Robblee","year":"2020","journal-title":"Headache"},{"issue":"1","key":"10.1016\/j.clineuro.2022.107169_bib30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s40120-021-00245-4","article-title":"Real-world treatment profiles, clinical outcomes, and healthcare resource utilization of patients with migraine prescribed erenumab: a multicenter chart-review study of US headache centers","volume":"10","author":"Faust","year":"2021","journal-title":"Neurol. Ther."},{"issue":"13","key":"10.1016\/j.clineuro.2022.107169_bib31","doi-asserted-by":"crossref","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","article-title":"Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2","volume":"94","author":"Lipton","year":"2020","journal-title":"Neurology"}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846722000506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846722000506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T14:39:15Z","timestamp":1759588755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846722000506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":31,"alternative-id":["S0303846722000506"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2022.107169","relation":{},"ISSN":["0303-8467"],"issn-type":[{"value":"0303-8467","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and safety of erenumab in chronic migraine: A Croatian real-world experience","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2022.107169","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107169"}}